Opinion|Videos|September 4, 2024
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy
Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are your thoughts regarding cretostimogene as monotherapy versus a combination therapy? Could you comment on how you would use this in your clinical practice either as a monotherapy or combination therapy and which patients may benefit from either approach?
- Why is it important that urologists stay informed about advances in managing BCG-unresponsive NMIBC now that we have multiple therapeutic agents approved in this disease state?
- Please share any closing thoughts regarding the unmet needs that remain in the management of BCG-unresponsive NMIBC, along with the impact cretostimogene plus pembrolizumab combination therapy could have on the overall care of patients with NMIBC.
Advertisement
Related to this article
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.
All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.
Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
In this episode, Surena F. Matin, MD, FACS, discusses the evidence and practical considerations surrounding perioperative intravesical chemotherapy to reduce bladder recurrence after nephroureterectomy.
NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5